Intrahepatic cholestasis of pregnancy (ICP) is a disorder of defective bile acid transport with systemic accumulation of bile acids. Women typically present with diffuse pruritus in the third trimester of pregnancy. The incidence of ICP varies geographically with rates as high as 5 to 10% in Chile, Bolivia, and Scandinavia. ICP is associated with adverse pregnancy outcomes, including meconium staining of the amniotic fluid, fetal asphyxial events, preterm delivery, 1 and sudden intrauterine fetal demise. 2 We present the most severe case published in the literature of biopsy-proven recurrent ICP presenting in the first trimester of pregnancy.
Intrahepatic cholestasis of pregnancy (ICP) is a disorder of defective bile acid transport with systemic accumulation of bile acids. Women typically present with diffuse pruritus in the third trimester of pregnancy. The incidence of ICP varies geographically with rates as high as 5 to 10% in Chile, Bolivia, and Scandinavia. ICP is associated with adverse pregnancy outcomes, including meconium staining of the amniotic fluid, fetal asphyxial events, preterm delivery, 1 and sudden intrauterine fetal demise. 2 We present the most severe case published in the literature of biopsy-proven recurrent ICP presenting in the first trimester of pregnancy.
Case Study
A 26-year-old Guatemalan female gravida 6, para 0231 at 7 5/7 weeks gestation developed diffuse generalized itching, dark urine, and light colored stools. By patient report, her first pregnancy in 2007 was complicated by ICP at 20 weeks gestation resulting in vaginal delivery at 35 weeks gestation after preterm premature rupture of membranes. Her subsequent pregnancy in 2010 was complicated by ICP beginning at 10 weeks gestation resulting in an intrauterine fetal demise at 27 weeks gestation; she was subsequently delivered by primary cesarean section due to heavy vaginal bleeding during her induction of labor. Meconium staining and intervillous fibrin deposition were identified on placental pathology. In addition, the patient reported a history of intense pruritus with elevated transaminases and bilirubin while using NuvaRing (Merck Corp., Kenilworth, NJ) before pregnancy. She reported no relevant family history. On physical examination, the patient was in visible distress, continuously itching throughout the interview. She had diffuse excoriations. She had no abdominal tenderness and her examination was otherwise unremarkable and her vital signs were within normal limits. Fetal status was reassuring.
First trimester laboratory studies in the current gestation returned as follows: aspartate aminotransferase (AST) 69 U/L (normal: 7-35 U/L), alanine aminotransferase (ALT) 107 U/L (normal: 1-30 U/L), total bilirubin 0.5 mg/dL (normal: 0.1-0.9 mg/dL), alkaline phosphatase 278 U/L (normal: 29-92 U/L). Ursodiol 300 mg twice daily was prescribed as well as hydroxizine and diphenhydramine as needed. The total bile Keywords ► severe recurrent ICP ► first trimester ► intrauterine fetal demise ► preterm birth
Abstract
Background Intrahepatic cholestasis of pregnancy (ICP) is a disorder of defective bile acid transport that results in systemic accumulation of bile acids and typically presents in the third trimester of pregnancy with intense pruritus. A positive linear correlation exists between total bile acid level and poor pregnancy outcome, and labor is typically induced at 37 weeks gestation to prevent intrauterine fetal demise (IUFD). Case Study We present the most severe reported case of recurrent ICP presenting early in the first trimester. The patient was delivered by repeat cesarean section at 31 6/7 weeks gestation resulting in a viable female infant. Conclusion Iatrogenic preterm delivery may be indicated in early-severe recurrent ICP to prevent IUFD, but more research is needed.
acid level at 13.5 weeks gestation was 243.6 µmol/L (normal: 0-11.3 µmol/L], at which time the dose of ursodiol was increased to 500 mg twice daily, and S-adenosyl methionine 500 mg twice daily was initiated. Repeat bile acids at 16 3/7 weeks gestation were 215 µmol/L with a total bilirubin level of 2.8 mg/dL, direct bilirubin 1.5 mg/dL, AST 39 U/L, and ALT 34 U/L. She was referred to hepatology to rule out other differential diagnoses. Additional laboratory evaluation showed: antinuclear antibody negative, antimitochondrial antibody negative, anti-liver kidney microsomal antibody negative, α-1-antitrypsin 179 mg/dL (normal: 100-300 mg/dL), antismooth muscle antibody positive with a titer of 1:80, gamma-glutamyl transpeptidase 36 IU/L (normal: 0-51 U/L), amylase 52 U/L (normal: 23-85 U/L), lipase 27 U/L (normal: 0-160 U/L), ceruloplasmin 97.1 mg/dL (normal: 20-50mg/ dL), and repeat total bile acid level > 191.3 µmol/L. Viral hepatology studies were negative for hepatitis A, B, and C. Abdominal ultrasound revealed a normal size liver without evidence of gallstones; there were no dilated extrahepatic or intrahepatic bile ducts and no signs of portal hypertension or other vascular abnormalities. Due to a positive antismooth muscle antibody, core liver biopsy was performed at 22 2/7 weeks gestation to rule out autoimmune hepatitis, primary biliary cirrhosis, and primary sclerosing cholangitis. Histology revealed pure intrahepatic cholestasis (►Fig. 1). The patient experienced worsening, debilitating symptoms at 24 2/7 weeks gestation, and cholestyramine 4 g daily was added to her existing medication regimen. She declined a trial of dexamethasone. At 26 0/7 weeks gestation, cholestyramine was increased to 16 g daily. She was hospitalized at 27 0/7 weeks gestation for betamethasone administration and four times daily fetal monitoring, given both the severity of her ICP and her history of a preterm stillbirth. She declined continuous fetal monitoring. She underwent planned repeat caesarean section at 31 6/7 weeks gestation after receiving 12 hours of magnesium sulfate for fetal neuroprophylaxis. She delivered a viable female infant weighing 1,758 g with Apgar scores of 8 at 1 minute, 2 at 5 minutes, and 9 at 10 minutes. The infant required intubation and admission to the neonatal intensive care unit for respiratory distress syndrome and prematurity, and was discharged on day 34 of life in stable condition. The patient's condition improved postpartum and she followed a routine postpartum course.
Comment
A comprehensive review of the literature was performed using PubMed with the search terms "cholestasis," "ICP," "obstetric cholestasis" AND "pregnancy." Our case represents the highest reported elevated bile acids occurring in the first trimester of pregnancy, with a total bile acid level of > 240 µmol/L at 13 weeks gestation (►Table 1). There are only five additional cases of severe first trimester ICP identified in the literature It is generally accepted that ICP is an indication for earlyterm delivery at 37 weeks gestation due to the increased risk of fetal demise.
12 However, optimal management for women with early recurrent severe ICP is not known. He et al, identified 21 cases of intrauterine fetal demise in women with ICP in which the average gestational age of death was 33.8 weeks, and the earliest gestational age of fetal demise attributable to ICP was at 29 weeks gestation. 13 Given this limited data combined with the severity of this case's ICP and her personal history of a 27 week fetal demise from ICP, we opted for delivery at 32 weeks gestation, since we believed the risks of prematurity to be less than the risk of intrauterine fetal demise. Additional research is needed to further evaluate the role of iatrogenic preterm delivery Note: ►Table 2 shows cases reported in the literature whereby severe intrahepatic cholestasis of pregnancy occurred in the first trimester.
